Last Update: Mar 29, 2023
Survey Among Healthcare Professionals and MS Patients/Caregivers in Selected European Countries to Evaluate the Knowledge Required for the Safe Use of Mayzent Identifier:
Novartis Reference Number:CBAF312A2006
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

Survey to be completed independently by HCPs (neurologists treating patients with MS and MS specialist nurses) and patients/caregivers.

The web-based survey is conducted in EU countries where Mayzent (siponimod) is available on the market and reimbursed for at least 6 months, to capture the knowledge and understanding of specific Mayzent safety measures by HCPs and patients/caregivers with access to Mayzent (siponimod).

Multiple Sclerosis
Dec 02, 2021
Sep 30, 2024
18 Years - (Adult, Older Adult)

Eligibility Criteria

Inclusion Criteria:

Physicians will be considered eligible for the survey if they meet the following screening criteria:

Care for relapsing MS (RMS) patients
Personally prescribed disease modifying therapies to MS patients, and;
Have prescribed Mayzent (siponimod) in at least 1 SPMS patient.

Nurses will be considered eligible for the survey if they:

Provide supportive care for RMS patients
Have initiated and/or managed the use of Mayzent (siponimod) in at least 1 SPMS patient.

Patient inclusion criteria include:

- Have been initiated onto Mayzent (siponimod) to treat their MS since reimbursement

Exclusion Criteria:


Study Location

Novartis Investigative Site



Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals